Development of functional nanoparticles can be encumbered by unanticipated material properties and biological events, which can affect nanoparticle effectiveness in complex, physiologically relevant systems [1] [2] [3] . Despite the advances in bottom-up nanoengineering and surface chemistry, reductionist functionalization approaches remain inadequate in replicating the complex interfaces present in nature and cannot avoid exposure of foreign materials. Here we report on the preparation of polymeric nanoparticles enclosed in the plasma membrane of human platelets, which are a unique population of cellular fragments that adhere to a variety of disease-relevant substrates [4] [5] [6] [7] . The resulting nanoparticles possess a right-side-out unilamellar membrane coating functionalized with immunomodulatory and adhesion antigens associated with platelets. Compared to uncoated particles, the platelet membrane-cloaked nanoparticles have reduced cellular uptake by macrophage-like cells and lack particle-induced complement activation in autologous human plasma. The cloaked nanoparticles also display platelet-mimicking properties such as selective adhesion to damaged human and rodent vasculatures as well as enhanced binding to platelet-adhering pathogens. In an experimental rat model of coronary restenosis and a mouse model of systemic bacterial infection, docetaxel and vancomycin, respectively, show enhanced therapeutic efficacy when delivered by the platelet-mimetic nanoparticles. The multifaceted biointerfacing enabled by the platelet membrane cloaking method provides a new approach in developing functional nanoparticles for diseasetargeted delivery.
Owing to their role as circulating sentinels for vascular damage and for invasive microorganisms, platelets have inspired the design of many functional nanocarriers [8] [9] [10] [11] [12] [13] . The multitude of platelet functions stem from a unique set of surface moieties responsible for immune evasion 14, 15 , subendothelium adhesion 5, 16 , and pathogen interactions 6, 7 . By adopting a cell membrane cloaking technique [17] [18] [19] , we demonstrate the preparation of platelet membrane-cloaked nanoparticles (PNPs) consisting of a biodegradable polymeric nanoparticle core shielded entirely in the plasma membrane of human platelets. Several inherent platelet properties, including immunocompatibility, binding to injured vasculature and pathogen adhesion, as well as their therapeutic implications, were studied (Extended Data Fig. 1a ).
PNPs were prepared by fusing human platelet membrane with 100-nm poly(lactic-co-glycolic acid) (PLGA) nanoparticles. Before platelet collection, blood and plasma samples were mixed with EDTA, which prevents platelet aggregation by deactivating fibrinogenbinding integrin aIIbb3 (ref. 20) . Platelets were then processed for nanoparticle membrane cloaking (Extended Data Fig. 1b) . Physicochemical characterizations revealed that the final PNPs were approximately 15 nm larger than the uncoated PLGA nanoparticles (bare NPs) and possessed an equivalent surface charge to that of platelets and platelet membrane-derived vesicles (platelet vesicles) (Fig. 1a) . Transmission electron microscopy (TEM) visualization showed the formation of distinctive nanoparticulates and consistent unilamellar membrane coatings over the polymeric cores ( Fig. 1b and Extended Data Fig. 2 ). Improved colloidal stability was observed with the PNPs compared to bare NPs (Fig. 1c) , which is attributable to the stabilizing effect by the plasma membrane's hydrophilic surface glycans 21 . Translocation of platelet membrane protein content, including immunomodulatory proteins, CD47, CD55, and CD59 14, 15 , integrin components, aIIb, a2, a5, a6, b1, and b3, and other transmembrane proteins, GPIba, GPIV, GPV, GPVI, GPIX, and CLEC-2 5, 16 , onto the nanoparticles was examined by western blotting (Fig. 1d and Extended Data Fig. 3 ). Platelets derived from multiple protocols were prepared in parallel for comparison, and it was observed that the PNP preparation resulted in membrane protein retention and enrichment that was very similar across the different platelet sources (Extended Data Fig. 3 ). Notably, platelets derived from blood treated with heparin, an anticoagulant that inactivates thrombin rather than platelets, showed evidence of higher platelet activation including increased GPIba cleavage and CLEC-2 oligomerization 22 . Using blood anticoagulated with EDTA as the platelet source, a right-sideout membrane orientation on the PNPs was verified by both immunogold staining and flow cytometric analysis with antibodies targeting either the intracellular or extracellular domain of CD47 ( Fig. 1e and Extended Data Fig. 4 ). Pro-thrombotic, platelet-activating molecules such as thrombin, ADP and thromboxane were removed in the PNP formulation ( Fig. 1f-h ), thereby permitting PNP administration with little risk of a thrombotic response (Fig. 1i) .
The platelet-mimicking functionalities of PNPs were first studied via binding of the particles to human type IV collagen, a primary subendothelial component 23 . Fluorescently labelled PNPs, along with bare NPs and red blood cell membrane-cloaked nanoparticles (RBCNPs), were incubated on collagen-coated plates. The PNPs showed significantly enhanced retention compared to bare NPs and RBCNPs (Fig. 2a) , indicating that the collagen adhesion was membrane-typespecific. Reduced PNP retention on non-collagen-coated plates and in the presence of anti-GPVI antibodies supports a specific collagenplatelet membrane interaction attributable to the presence of membrane glycoprotein receptors for collagen 16 (Extended Data Fig. 3 ). Further examination of the differential binding of PNPs to endothelial and collagen surfaces was performed using collagen-coated tissue culture slides seeded with human umbilical vein endothelial cells (HUVECs). PNPs adhered primarily outside of areas encompassed by the cells (Fig. 2b and Extended Data Fig. 5a-g ). In addition, the PNPs were incubated with the extracellular matrix derived from decellularized human umbilical cord arteries. After PBS washes, scanning electron microscopy (SEM) revealed a significant number of PNPs remaining on the fibrous structures on the luminal side of the artery ( Fig. 2c and Extended Data Fig. 5h, i) .
Examination of PNPs' immunocompatibility was conducted using differentiated human THP-1 macrophage-like cells. The platelet membrane cloaking reduced particle internalization in a CD47-specific manner 24 , as blocking by anti-CD47 antibodies increased the cellular uptake (Fig. 2d) . The PNPs were further investigated for their interactions with the complement system based on quantifications of C4d and Bb split products. After incubation in human plasma, complement activation was observed with bare NPs, reflecting their susceptibility to opsonization as well as the spontaneous reaction between C3 thioesters and the hydroxyl groups on the PLGA particles 25 . In contrast, an equal amount of PNPs mixed with autologous plasma showed no observable complement activation (Fig. 2e, f) . This suppression of the complement system can be attributed to membrane-bound complement regulator proteins such as CD55 and CD59 (ref. 26 ; Extended Data Fig. 3 ). This result also attests to the completeness of the membrane cloaking, which shields the polymeric cores from plasma exposure and minimizes the risk of anaphylatoxin generation frequently associated with injectable nanocarriers 27 . The therapeutic potential of PNPs was first examined by assessing their selective adherence to damaged vasculatures. A segment of the human carotid artery was surgically scraped to expose the subendothelial matrix (Fig. 3a) . The intact and damaged artery samples were subsequently incubated with fluorescently labelled PNPs for 30 s followed by repeated PBS washes. The resulting arterial cross-sections and en face visualizations revealed that the denuded artery was more prone to PNP adhesion than the intact artery (Fig. 3b, c) . In Fig. 3c , it can also be observed that PNPs bind preferentially to the edges of the intact artery, where subendothelium was exposed upon tissue incision. This selective PNP adhesion was further validated in a rat model of angioplasty-induced arterial injury. Pharmacokinetic analyses and biodistribution studies showed that .90% of the PNPs were distributed to tissues 30 min after intravenous injection, with liver and spleen being the primary distribution organs (Extended Data Fig. 6a, b) . A comprehensive blood chemistry panel analysis revealed that the PNPs did not inflict observable adverse effects in the rats (Extended Data  Fig. 6c ). Selective particle binding to the denuded artery was observed upon examination of the aortic branch 2 h after administration of PNP ( Fig. 3d and Extended Data Fig. 7) . The PNPs were localized on the luminal side above the smooth muscle layer (Fig. 3e) , and retention at the injury site lasted for at least 5 days (Fig. 3f) . In a rat model of coronary restenosis, therapeutic relevance of platelet-mimicking delivery was examined using docetaxel-loaded PNPs (PNP-Dtxl) (Extended Data Fig. 8 ). PNP-Dtxl treatment on day 0 and 5 at 0.3 mg per kg body weight (mg kg
21
) of docetaxel dosing potently inhibited neointima growth in balloon-denuded rats as evidenced by the arterial cross-sections collected on day 14 (Fig. 3g, h and Extended Data Fig. 9 ). To evaluate the vascular remodelling quantitatively, intima-to-media ratio (I/M) and luminal obliteration were calculated. Compared to free docetaxel, which resulted in an I/M of 0.76 6 0.18 (mean 6 s.d.) and a luminal obliteration of 33.6%, PNP-Dtxl yielded significantly lower values of 0.18 6 0.06 and 8.0%, respectively (P # 0.0001) (Fig. 3i, j) . These results demonstrate the benefit of PNP-directed delivery in improving drug localization to diseased vasculatures.
We further examined the therapeutic potential of PNPs against platelet-adhering pathogens. Opportunistic bacteria, including several LETTER RESEARCH strains of staphylococci and streptococci, exploit platelets by both direct and indirect adherence mechanisms for tissue localization and immune evasion 6 . To demonstrate that PNPs can exploit the inherent bacterial adherence mechanism for targeted antibiotics delivery, MRSA252, a strain of methicillin-resistant Staphylococcus aureus expressing a serine-rich adhesin for platelets (SraP) 28 , was used as a model pathogen for particle adhesion study. After 10 min of incubation between formalin-fixed MRSA252 and different nanoformulations, the collected bacteria showed preferential binding by PNPs (Fig. 4a) , exhibiting a 12-fold increase in PNP retention compared to bare NPs ( Spleen bacterial count (CFU)
P N P -V a n c P B S V a n c R B C N P -V a n c P N P -V a n c -1 0 P B S V a n c -6 0 V a n c -1 0 R B C N P -V a n c -1 0 P N P -V a n c -1 0 P B S V a n c -6 0 V a n c -1 0 R B C N P -V a n c - ) was examined in a mouse model of systemic infection with MRSA252. After 3 days of treatments, bacterial loads in different organs including blood (d), heart (e), lung (f), liver (g), spleen (h) and kidney (i) were quantified. Bars represent means 6 s.e.m. (n 5 14). *P # 0.05, **P # 0.01, ***P # 0.001, ****P # 0.0001.
of PNPs was further evaluated using vancomycin-loaded formulations. In an in vitro antimicrobial study, live MRSA252 bacteria were briefly incubated with free vancomycin, vancomycin-loaded RBCNPs (RBCNP-Vanc), or vancomycin-loaded PNPs (PNP-Vanc) followed by a wash and culturing in fresh media. The PNP-Vanc formulation showed statistically significant improvement in MRSA252 reduction that corroborates the targeting effect of the particles (Fig. 4c ). An in vivo antimicrobial efficacy study was further conducted using a mouse model of systemic MRSA252 infection. Mice systemically challenged with 6 3 10 6 colony-forming units (CFU) of MRSA252 received once daily intravenous treatment of free vancomycin, RBCNP-Vanc, or PNP-Vanc for 3 days at 10 mg kg 21 of vancomycin. A control group of high-dose vancomycin treatment in which infected mice received free vancomycin at 30 mg kg 21 twice daily was conducted in parallel. 24 h after the last treatment, bacterial enumeration at the primary infection organs showed that the PNP-Vanc resulted in the lowest mean bacterial counts across all organs (Fig. 4d-i) . Statistical analyses revealed significance between PNP-Vanc and free vancomycin at equivalent dosage in the lung, liver, spleen and kidney. In comparison to free vancomycin at sixfold the dosage, PNP-Vanc showed significantly better antimicrobial efficacy in the liver and spleen and was at least as effective in the blood, heart, lung and kidney. Notably, compared to RBCNP-Vanc, PNP-Vanc showed significantly higher potency in the heart, lung, liver and spleen, reflecting membrane-specific modulation of nanoparticle performance. The study validates the feasibility of harnessing biomembrane interfaces to improve infectious disease treatment.
The vast medical relevance of platelets has inspired many plateletmimicking systems that target dysfunctional vasculature in cardiovascular diseases 8, 9 , traumas 10, 11, 13 , cancers 12 and acute inflammations 29 . The present PNP platform exploits platelet membrane in its entirety to enable biomimetic interactions with proteins, cells, tissues and microorganisms. Towards translation, the platform would benefit from existing infrastructures and logistics for transfusion medicine, polymeric nanotherapeutics and cell-derived pharmaceutics. Previous work on the cell membrane cloaking approach demonstrated high cloaking efficiency 30 and viable storage 18 upon platform optimization (Extended Data Fig. 2f-h ). By employing large-scale purification and dispersion techniques commonly applied to biologics, reliable platelet membrane derivation and PNP production can be envisioned.
Online Content Methods, along with any additional Extended Data display items and Source Data, are available in the online version of the paper; references unique to these sections appear only in the online paper.
METHODS
Human platelet isolation and platelet membrane derivation. Human type O 2 blood anti-coagulated with 1.5 mg ml 21 EDTA was purchased from BioreclamationIVT and processed for platelet collection approximately 16 h after blood collection. Unless otherwise stated, platelets derived from this commercial blood source were used in this study. Fresh human type O 2 blood was also collected with dipotassium EDTA-treated or lithium heparin-treated blood collection tubes (Becton, Dickinson and Company) under the approval of the Institutional Review Board (IRB) at the University of California, San Diego, USA. Patients consented to use of their blood samples for this study before collection. The freshly drawn blood was processed for platelet collection approximately 30 min after blood draw. In addition, unexpired (in-dated) human type O 2 platelet rich plasma (PRP) in acid-citrate-dextrose (ACD) was purchased from the San Diego Blood Bank. Samples not originally drawn in EDTA were adjusted to a concentration of 5 mM EDTA before platelet collection. To isolate platelets, the blood and plasma samples were centrifuged at 100g for 20 min at room temperature to separate red blood cells and white blood cells. The resulting PRP was then centrifuged at 100g for 20 min to remove remaining blood cells. PBS buffer containing 1 mM of EDTA and 2 mM of prostaglandin E1 (PGE1, Sigma Aldrich) was added to the purified PRP to prevent platelet activation. Platelets were then pelleted by centrifugation at 800g for 20 min at room temperature, after which the supernatant was discarded and the platelets were resuspended in PBS containing 1 mM of EDTA and mixed with protease inhibitor tablets (Pierce). 1.5 ml aliquots of platelet solution containing ,3 3 10 9 platelets were prepared and used to cloak 1 mg of PLGA nanoparticles.
Platelet membrane was derived by a repeated freeze-thaw process. Aliquots of platelet suspensions were first frozen at 280 uC, thawed at room temperature, and pelleted by centrifugation at 4,000g for 3 min. After three repeated washes with PBS solution mixed with protease inhibitor tablets, the pelleted platelet membranes were suspended in water and sonicated in a capped glass vial for 5 min using a Fisher Scientific FS30D bath sonicator at a frequency of 42 kHz and a power of 100 W. The presence of platelet membrane vesicles was verified by size measurement using dynamic light scattering (DLS) and morphological examination by transmission electron microscopy (TEM). Platelet membrane-cloaked nanoparticle (PNP) preparation and characterization. 100 nm polymeric cores were prepared using 0.67 dl g 21 carboxylterminated 50:50 poly(lactic-co-glycolic) acid (PLGA) (LACTEL Absorbable Polymers) in a nanoprecipitation process. 1 ml of 10 mg ml 21 PLGA solution in acetone was added dropwise to 3 ml of water. For fluorescently labelled nano formulations, 1,19-dioctadecyl-3,3,39,39-tetramethylindodicarbocyanine perchlorate (DiD, excitation 5 644 nm/emission 5 665 nm, Life Technologies) was loaded into the polymeric cores at 0.1 wt%. The mixture was then stirred in open air for 1 h and placed in vacuum for another 3 h. The resulting nanoparticle solution was filtered with 10 kDa MWCO Amicon Ultra-4 Centrifugal Filters (Millipore). Platelet membrane cloaking was then accomplished by dispersing and fusing platelet membrane vesicles with PLGA particles by sonication using an FS30D bath sonicator at a frequency of 42 kHz and a power of 100 W for 2 min. The size and the surface zeta potential of replicate PNP samples (n 5 3) were obtained by dynamic light scattering (DLS) measurements using a Malvern ZEN 3600 Zetasizer. PBS stability was examined by mixing 1 mg ml 21 of PNPs in water with 2 3 PBS at a 1:1 volume ratio. Storability of PNPs was examined by suspending PNPs in 10% sucrose. The nanoparticle solutions were subject to either a freeze-thaw cycle or lyophilization followed by resuspension. The resulting particle solution was then monitored for particle size using DLS. The structure of PNPs was examined with TEM after negative staining with 1 wt% uranyl acetate using an FEI 200 kV Sphera microscope. RBCNPs were prepared using the same polymeric cores and RBC membranes of equivalent total surface area to the platelet membranes following a previously described protocol 16 . The RBCNPs were characterized using DLS and had similar size and zeta potential as the PNPs.
Docetaxel-loaded PLGA nanoparticle cores were prepared by a nanoprecipitation process. 10 wt% docetaxel was added to 5 mg PLGA in acetone and precipitated dropwise into 3 ml water. The solvent was evaporated as described above and free docetaxel was removed by repeated wash steps. Vancomycin-loaded nanoparticles were synthesized using a double emulsion process. The inner aqueous phase consisted of 25 ml of vancomycin (Sigma Aldrich) dissolved in 1 M NaOH at 200 mg ml 21 . The outer phase consisted of 500 ml of PLGA polymer dissolved in dichloromethane at 50 mg ml 21 . The first emulsion was formed by sonication at 70% power pulsed (2 s on/1 s off) for 2 min on a Fisher Scientific 150E Sonic Dismembrator. The resulting emulsion was then emulsified in aqueous solution under the same dispersion setting. The final water/oil/water emulsion was added to 10 ml of water and the solvent was evaporated in a fume hood under gentle stirring for 3 h. The particles were collected by centrifugation at 80,000g in a Beckman Coulter Optima L-90K Ultracentrifuge. The particles were washed and resuspended in water. Upon preparation of drug-loaded PLGA cores, cell membrane coating was performed by adding the appropriate surface area equivalent of either platelet or red blood cell membrane followed by 3 min of sonication in a Fisher Scientific FS30D Bath Sonicator. Particle size, polydispersity (PDI), and surface zeta potential were characterized using DLS. Drug loading yield and release rate of replicate samples (n 5 3) were quantified by high performance liquid chromatography (HPLC). Drug release was determined by dialyzing 500 ml of particle solution at a concentration of 2.67 mg ml 21 in PBS using 3.5 K MWCO Slide-A-Lyzers (Thermo Scientific). Examination of platelet membrane proteins. PNPs were purified from unbound proteins or membrane fragments by centrifugation at 16,000g in 10% sucrose. Platelet-rich plasma, platelets, platelet membrane vesicles, and PNPs were then normalized to equivalent overall protein concentration using a Pierce BCA Protein Assay Kit (Life Technologies). To examine the effect of different platelet derivation protocols on the membrane protein expression, platelets collected from commercial blood anti-coagulated in EDTA, freshly drawn blood anti-coagulated in EDTA or heparin, and transfusion-grade PRP in ACD were prepared in parallel. All platelets were processed using the aforementioned platelet membrane derivation protocol for PNP preparation. The samples containing equivalent total proteins were then lyophilized, prepared in lithium dodecyl sulfate (LDS) sample loading buffer (Invitrogen), and separated on a 4-12% Bis-Tris 17-well minigel in MOPS running buffer using a Novex Xcell SureLock Electrophoresis System (Life Technologies). Identification of key membrane proteins by western blotting was performed using primary antibodies including mouse anti-human CD47 (eBioscience, B6H12), mouse anti-human CD55 (Biolegend, JS11), mouse antihuman CD59 (Biolegend, p282 (H19)), mouse anti-human integrin aIIb subunit (Biolegend, HIP8), rat anti-human integrin a2 subunit (R&D Systems, 430907), rabbit anti-human integrin a5 subunit (Abgent, AP12204c), mouse anti-human integrin a6 subunit (Abgent, AM1828a), mouse anti-human integrin b1 subunit (R&D Systems, 4B7R), mouse anti-human integrin b3 subunit (Biolegend, VI-PL2), mouse anti-human GPIba (R&D Systems, 486805), mouse anti-human GPIV (R&D Systems, 877346), mouse anti-human GPV (Santa Cruz Biotech, G-11), rat anti-human GPVI (EMD Millipore, 8E9), rabbit anti-human GPIX (Santa Cruz Biotech, A-9), and mouse anti-human CLEC-2 (Genetex, 8J24). A goat anti-mouse IgG-HRP conjugate (Biolegend, Poly4053), a goat anti-rat IgG-HRP conjugate (Biolegend, Poly4054), or a donkey anti-rabbit IgG-horseradish peroxidase (HRP) conjugate (Biolegend, Poly4064) was used for secondary staining based on the isotype of the primary antibody. MagicMark XP western protein standard (Invitrogen) was used as a molecular weight ladder. The nitrocellulose membrane was then incubated with ECL western blotting substrate (Pierce) and developed with the Mini-Medical/90 Developer (ImageWorks). Examination of protein sidedness on PNPs. For immunogold staining, a drop of the PNP solution (1 mg ml 21 ) was deposited onto a glow-discharged carboncoated grid. The grid was then washed 3 times with PBS, blocked with 1% BSA for 15 min, and stained with 0.5 mg ml 21 of anti-CD47 targeted to either the intracellular or extracellular domain of the protein. After 1 h of incubation, the samples were rinsed with PBS containing 1% BSA for 6 times and stained with anti-rabbit IgG-gold conjugate (5 nm) solution (Sigma Aldrich) for another hour. After 6 PBS washes, the samples were fixed with 1% glutaraldehyde in PBS for 5 min and washed with water 6 times. The sample grids were subsequently stained with 2% vanadium solution (Abcam) and visualized using an FEI 200 kV Sphera microscope.
For flow cytometric analysis, 2.0 mm carboxyl-functionalized polystyrene beads at a concentration of 4 wt% (Life Technologies) were functionalized with rabbit N terminus-targeted (extracellular) anti-human CD47 (Aviva Biosystems, ARP63284), rabbit intracellular-domain-targeted anti-CD47 (Genetex, EPR4150(2)), or rabbit anti-ovalbumin (Abcam, ab1221) as a sham antibody by EDC/NHS chemistry. The resulting antibody-modifed beads were re-suspended in 100 ml of DI water. The bead solution was first incubated with 1 mg of bovine serum albumin (BSA, Sigma Aldrich) to block non-specific interactions and then mixed with 1 ml of fluorescently labelled PNPs (200 mg ml
21
). The mixture solution was incubated at room temperature for 2 h and then centrifuged to remove the unbound PNPs. The collected polystyrene beads were then subjected to flow cytometric analysis. Platelet aggregation assay. Platelets, platelet membrane vesicles, and PNPs of equivalent membrane content were prepared and examined for platelet-activating molecules, including thrombin, ADP, and thromboxane, using a SensoLyte 520 Thrombin Activity Assay Kit (AnaSpec), ADP Colorimetric/Fluorometric Assay Kit (Sigma Aldrich), and Thromboxane B2 (TXB 2 ) ELISA Kit (Enzo Life Sciences), respectively, based on the manufacturers' instructions. Each sample was assayed in replicate (n 5 3).
Aggregation of platelets in the presence of PNPs was assessed using a spectrophotometric method. 1 ml aliquot of platelet rich plasma (PRP) was first prepared RESEARCH LETTER from human whole blood with sodium citrate as the anti-coagulant. The plasma was then loaded into a cuvette followed by addition of 500 ml of 2 mg ml 21 PNPs in PBS solution. As negative and positive controls, the PRP was mixed with 500 ml of PBS or 500 ml of PBS containing 0.5 IU ml 21 of human thrombin (Sigma Aldrich), respectively. The cuvettes were immediately placed in a TeCan Infinite M200 reader and monitored for change in absorbance at 650 nm over time, and platelet aggregation was observed based on the reduction of turbidity. Collagen binding study. Collagen type IV derived from human placenta (Sigma Aldrich) was reconstituted to a concentration of 2.0 mg ml 21 in 0.25% acetic acid. 200 ml of the collagen solution was then added to each well of a 96-well assay plate and incubated overnight at 4 uC. Prior to the collagen binding study, the plate was blocked with 2% BSA and washed three times with PBS. For the collagen binding study, 100 ml of 1 mg ml 21 DiD-loaded nanoformulations in water were added into replicate wells (n 5 6) of collagen-coated or non-collagen-coated plates. After 30 s of incubation, the plates were washed three times. Retained nanoparticles were then dissolved with 100 ml of DMSO for fluorescence quantification using a TeCan Infinite M200 reader. Differential adhesion to endothelial and collagen surfaces. Collagen type IV was coated on 8-well Lab-Tek II chamber slides (Nunclon) as described above. The collagen-coated chamber slides were used to seed primary HUVECs obtained from the American Type Culture Collection and cultured in HUVEC Culture Medium (Sigma Aldrich) supplemented with 10% fetal bovine serum for 24 h. The cells were then incubated with 1 mg ml 21 DiD-loaded PNPs in PBS at 4 uC for 30 s. Next the cells were washed with PBS three times and fixed with tissue fixative (Millipore) for 30 min at room temperature. Fluorescence staining was done with 49,6-diamidino-2-phenylinodle (DAPI, Life Technologies) for the nuclei and 22-(n-(7-nitrobenz-2-oxa-1,3-diazol-4-yl)amino)-23,24-bisnor-5-cholen-3b-ol (NBD cholesterol, Life Technologies) for the cytosol before mounting the cells in ProLong Gold antifade reagent (Life Technologies) and imaged using a DeltaVision deconvolution scanning fluorescence microscope. z-stacks were collected at 0.25 mm intervals over 10 mm. The images were deconvolved and superimposed. DiD fluorescence signal over collagen and endothelial surfaces as defined by the boundaries of NBD fluorescence were analysed using ImageJ. PNP retention over collagen and endothelial surfaces was quantified based on distinct images (n 5 10) in which the average fluorescence per unit area was analysed. Cellular uptake study with macrophage-like cells. THP-1 cells were obtained directly from the American Type Culture Collection and used without further authentication or testing for mycoplasma contamination. The cells were maintained in RPMI 1640 media (Life Technologies) supplemented with 10% FBS (Sigma Aldrich). THP-1 cells were differentiated in 100 ng ml 21 phorbol myristate acetate (PMA, Sigma Aldrich) for 48 h and differentiation was visually confirmed by cellular attachment to Petri dishes. For the cellular uptake study, the differentiated macrophage-like cells were incubated in replicate wells (n 5 3) with DiD-loaded PNPs, anti-CD47 blocked PNPs, and bare NPs at 100 mg ml 21 in culture media. After 30 min of incubation at 37 uC, the macrophage-like cells were scraped off the Petri dish and washed three times in PBS to remove non-internalized particles. Flow cytometry was performed to examine nanoparticle uptake by the macrophage-like cells. All flow cytometry studies were conducted on a FACSCanto II flow cytometer (BD Biosciences) and the data was analysed using FlowJo software from Tree Star. Statistical analysis was performed based on a twotailed, unpaired t-test. Complement activation study. To assess complement system activation, two complement split products (C4d and Bb) were analysed using enzyme-linked immunosorbent assay kits (Quidel Corporation). The nanoparticles were incubated in replicate aliquots (n 5 4) of human serum at a volume ratio of 1:5 in a shaking incubator (80 r.p.m.) at 37 uC for 1 h. The reaction was then stopped by adding 60 volumes of PBS containing 0.05% Tween-20 and 0.035% ProClin 300. Complement system activation of the nanoparticles was assayed following the manufacturer's instructions, and zymosan was used as a positive control. PNP adherence to human carotid artery. Human umbilical cord was collected under the approval of the Institutional Review Board (IRB) at the University of California, San Diego, USA, and human carotid arteries were collected under the approval of the IRB at the University of Southern California, USA. Patients consented to use of their samples for this study before collection. To derive decellularized arterial extracellular matrix (ECM), human arteries were carefully dissected from the umbilical cord and removed from the surrounding Wharton's jelly, and subsequently incubated in 2% sodium dodecyl sulfate (SDS, Sigma Aldrich) for 72 h. The decellularized tissue was then rinsed with PBS and incubated in PBS solution containing 200 mg ml 21 PNPs for 30 s. The sample was then transferred to PBS solution and rinsed extensively before examination by scanning electron microscopy (SEM). A control decellularized arterial tissue sample without PNP incubation was prepared and visualized for comparison.
To examine PNP binding on denuded vascular walls, approximately 2 mm thick fresh human carotid artery sections were dissected and placed in normal saline on ice and transported immediately to the laboratory for a PNP binding study. To create the vascular characteristics of damaged arteries, an excised artery sample was surgically scraped on its luminal side with forceps to remove the endothelial layer. Successful denudation was confirmed by microscopy visualization. Prior to the nanoparticle binding experiment, both damaged and non-damaged artery samples were rinsed with PBS solution. The PNP binding experiment was performed by incubating the arterial samples in PBS solution containing 200 mg ml 21 of DiD-loaded PNPs for 30 s. The samples were then transferred to PBS solution and rinsed extensively before visualization by fluorescence microscopy. Endogenous tissue components such as collagen and elastin were identified based on their autofluorescence, which excites and emits maximally at ,300 -500 nm and was captured using a FITC filter. DiD fluorescence was captured using a Cy5 filter to examine the deposition of PNPs. The arterial samples were imaged by a cross-sectional view of a histological section and a topdown view on the luminal side. The images were normalized to a reference illumination image for proper comparison. Pharmacokinetics, biodistribution and safety of PNPs in a rat model of angioplasty-induced arterial denudation. All animal experiments were performed in accordance with NIH guidelines and approved by the Animal Care Committee of the University of California, San Diego. For the pharmacokinetics study, adult male Sprague-Dawley rats weighing 300-350 g (Harlan Laboratories) were administered with DiD-labelled PNPs and their blood was collected at specific time points via tail-vein blood sampling for fluorescence quantification. For the safety study, rats were injected with 1 ml of 5 mg ml 21 of PNPs on day 0 and day 5 followed by blood collection on day 10 for comprehensive metabolic panel analysis. Rats receiving equivalent PBS injections were prepared as a control.
For the biodistribution and vasculature-targeting studies, adult male SpragueDawley rats weighing 300-350 g (Harlan Laboratories) were subjected to carotid balloon injury. In brief, the animals were anaesthetized with intraperitoneal ketamine (Pfizer) at 100 mg kg 21 and xylazine (Lloyd Laboratories) at 10 mg kg
. A ventral mid-line incision (, 2 cm) was made in the neck, and the left common carotid artery and carotid bifurcation were exposed by blunt dissection. Proximal of left carotid artery, inner carotid artery and external carotid artery were temporarily clamped to avoid excessive blood loss during the induction of the 2F Fogarty arterial embolectomy catheter (Edwards Lifesciences). The catheter was introduced into the left carotid artery through an arteriotomy on the external carotid artery. The catheter was slowly inflated to a determined volume (0.02 ml) and withdrawn with rotation for 3 times to denude the endothelium. The wound was later closed with 4-0 sutures.
After the wound closure, rats were injected intravenously with 1 ml of 5 mg ml 21 DiD-loaded PNPs in 10% sucrose. At specified time points after the injection, animals were euthanized by CO 2 inhalation. After perfusion with PBS, organs including heart, lung, liver, spleen, kidney, gut, blood, and aortic branch including both the left and right carotid arteries were carefully collected and homogenized for biodistribution analysis. The overall PNP distribution at the aortic branch was visualized using a Keyence BZ-X700 fluorescence microscope. To examine the local distribution of PNP, damaged and undamaged arteries were cut longitudinally and stained with DAPI solution. En face examination was done on the luminal surfaces of denuded and intact areas for the binding of PNPs. Sequences of images along the z-axis (0.5 mm per section) from the intima to media layers of the carotid arteries were acquired with an Olympus ix81 fluorescence microscope. The 3D reconstruction of the arterial wall from multisectional images was performed using Image J. To analyse the PNP retention, damaged and undamaged arteries collected at specified time points were homogenized, and their respective fluorescence was normalized to the liver fluorescence for comparison. All replicates represent different rats subjected to the same treatment (n 5 6). Treatment of experimental coronary restenosis. Sprague-Dawley rats after angioplasty-induced arterial denudation were randomly placed into groups. The nanoparticle treatment group was injected intravenously with 1 ml of 5 mg ml 21 docetaxel-loaded PNPs in 10% sucrose at a docetaxel dose of 0.3 mg kg 21 on day 0 and day 5. As controls, animals receiving PBS, free docetaxel, and empty PNPs were prepared. On day 14, animals were euthanized with an overdose of a ketamine-xylazine cocktail and perfused with PBS and 4% paraformaldehyde (PFA) at a pressure of 120-140 mm Hg. Segments of left and right carotid arteries were carefully dissected out, and the PFA-fixed carotid arteries were embedded with Tissue-Tek OCT compound (VWR International) in a tissue base mould and slowly submerged into pre-chilled 2-methyl butane until frozen completely. The frozen tissue block was then immediately stored at 280 uC until sectioning. Serial sectioning (15 mm per section) was performed with a Cyrotome cryostat machine (Leica), and the tissue sections were placed on polylysine-treated glass slides. Tissue sections on slides were dried at room temperature for 30 min before stain-
LETTER RESEARCH
ing. For immunohistochemistry, frozen sections on slides were first washed with PBS to remove residual OCT medium and then subjected to standard haematoxylin and eosin (H&E) staining. Areas of intima and media were analysed using Image J. Luminal obliteration is defined as the intima area/the area within the internal elastic lamina. Statistical analysis was performed using one-way ANOVA. No statistical methods were used to predetermine sample size. Studies were done in a non-blinded fashion. All replicates represent different rats subjected to the same treatment (n 5 6). Staphylococcus aureus (MRSA252) bacteria adherence study. MRSA252 obtained from the American Type Culture Collection was cultured on tryptic soy broth (TSB) agar (Becton, Dickinson and Company) overnight at 37 uC. A single colony was inoculated in TSB medium at 37 uC in a rotary shaker. Overnight culture was refreshed in TSB medium at a 1:100 dilution at 37 uC under shaking for another 3 h until the OD 600 of the culture medium reached approximately 1.0 (logarithmic growth phase). The bacteria were harvested by centrifugation at 5,000g for 10 min and then washed with sterile PBS twice and then fixed with 10% formalin for 1 h. The fixed bacteria were washed with sterile PBS and suspended in 10% sucrose to a concentration of 1 3 10 8 CFU ml
21
. For the nanoparticle adhesion study, aliquots of 0.8 ml of 1 3 10 8 CFU ml 21 MRSA252 were mixed with 1.2 ml of 200 mg ml 21 DiD-loaded PNPs, RBCNPs, or bare NPs in 10% sucrose for 10 min at room temperature. The bacteria were then isolated from unbound nanoparticles by repeated centrifugal washes in sucrose solution at 5,000g. The purified bacteria were then suspended in 10% sucrose for replicate measurements (n 5 3) by flow cytometric analysis and SEM imaging. Antimicrobial efficacy study. For the in vitro antimicrobial efficacy study, 5 3 10 6 CFU of MRSA252 was mixed with 500 ml of 20 mg ml 21 nanoparticles (4 wt% vancomycin loading) in saline. As controls, equivalent amounts of bacteria were incubated in either PBS or free vancomycin (0.8 mg ml
). After 10 min of incubation, bacteria were isolated from the solution by centrifugation at 2,500g for 5 min. The collected bacteria pellet was resuspended with 500 ml of TSB culture medium and incubated for 5 h. The resulting samples were serially diluted in PBS and spotted on TSB agar plates. After 24 h of culturing, the colonies were counted to determine the bacteria count in each sample. Replicates represent separate bacterial aliquots incubated with the same formulation (n 5 3).
For the in vivo antimicrobial efficacy study, vancomycin-loaded PNPs (PNPVanc) and vancomycin-loaded RBCNPs (RBCNP-Vanc) were suspended in 10% sucrose solution at 31.25 mg ml 21 (4 wt% vancomycin loading). An equivalent concentration of free vancomycin (1.25 mg ml
) was also suspended in 10% sucrose. Male CD-1 mice (Harlan Laboratories) weighing , 25 g were challenged intravenously with 6 3 10 6 CFU of MRSA252 suspended in 100 ml of PBS. 30 min after the bacteria injection, mice were randomly placed into separate groups and injected with 200 ml of PNP-Vanc, RBCNP-Vanc, free vancomycin (daily dosage: 10 mg kg 21 vancomycin), or PBS. To compare to the clinical dosing of vancomycin, a control group treated with twice daily dosing of 30 mg kg 21 free vancomycin was prepared (total daily dosage: 60 mg kg 21 vancomycin). The mice received their corresponding treatments from day 0 to 2. On day 3, blood was collected from the submandibular vein. The mice were then euthanized, perfused with PBS, and their organs were collected. The organs were homogenized using a Biospec Mini Beadbeater in 1 ml of PBS for 1 min, serially diluted in PBS by tenfold, and plated onto agar plates with a spotting volume of 50 ml. After 48 h of culture, bacterial colonies were counted to determine the bacterial load in each organ. Under the given experimental conditions, the detection limit was determined to be approximately 20 CFU per organ. Data points on the x-axis represent samples with no detectable bacterial colonies. It was confirmed that samples prepared from unchallenged mice had no detectable colonies. The data was tested for normal distribution using the Shapiro-Wilk test. For blood and heart, which contained non-normal distributions, statistical analysis was performed using Kruskal-Wallis test. For the other organs, in which all groups were normally distributed and variance criteria were met, statistical analysis was performed using one-way ANOVA. Grubbs' test was used to detect and remove statistical outliers. No statistical methods were used to predetermine sample size. Studies were done in a non-blinded fashion. Replicates represent different mice subjected to the same treatment (n 5 14). sucrose show that the particles retain their size and stability after a freezethaw cycle and re-suspension upon lyophilization (n 5 3). Bars represent means 6 s.d. g, Transmission electron micrograph shows retentions of the core-shell structure of PNPs after a freeze-thaw cycle in 10% sucrose. Scale bar, 100 nm. h, Transmission electron micrograph shows retentions of the coreshell structure of PNPs upon resuspension after lyophilization in 10% sucrose. Scale bar, 100 nm.
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Extended Data Figure 3 | Overall protein content on PNPs resolved by western blotting. Primary platelet membrane protein/protein subunits including CD47, CD55, CD59, aIIb, a2, a5, a6, b1, b3, GPIba, GPIV, GPV, GPVI, GPIX, and CLEC-2 were monitored in platelet rich plasma, platelets, platelet vesicles, and PNPs. Platelets derived from four different protocols, including commercial blood anti-coagulated in EDTA, freshly drawn blood anti-coagulated in EDTA, freshly drawn blood anti-coagulated in heparin, and transfusion-grade platelet rich plasma anti-coagulated in acid-citrate-dextrose (ACD), were examined to compare the membrane protein expression. Each sample was normalized to equivalent overall protein content before western blotting. It was observed that the PNP preparation resulted in membrane protein retention and enrichment very similar across the different platelet sources.
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Extended Data Figure 4 | Platelet membrane sidedness on PNPs.
a, Transmission electron micrograph of PNPs primary-stained with anti-CD47 (intracellular), secondary-stained with immunogold, and negatively stained with 2% vanadium. The immunogold staining revealed presence of intracellular CD47 domains on collapsed platelet membrane vesicles, but not on PNPs. b, Transmission electron micrograph of PNPs primary-stained with anti-CD47 (extracellular), secondary-stained with immunogold, and negatively stained with 2% vanadium. PNPs were shown to display extracellular CD47 domains.
All scale bars, 100 nm. c, 2 mm polystyrene beads were functionalized with anti-CD47 against the protein's extracellular domain, anti-CD47 against the protein's intracellular domain, or a sham antibody. Flow cytometric analysis of the different beads after DiD-loaded PNP incubation showed the highest particle retention to beads functionalized with anti-CD47 against the protein's extracellular domain. c, Comprehensive metabolic panel of rats after injections with human-derived PNPs and PBS (n 5 6). The rats received intravenous injections of PNPs and PBS on day 0 and day 5, and the blood test conducted on day 10 did not reveal significant changes between the two groups, indicating normal liver and kidney functions after the PNP administration. All bars and markers represent means 6 s.d.
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Extended Data Figure 7 | PNP targeting of damaged vasculatures upon intravenous injection to rats with angioplasty-induced arterial denudation. a, Fluorescence microscopy of the aortic branch revealed selective PNP binding to the denuded artery (right) as opposed to the undamaged artery (left) (PNP fluorescence in red). b, Fluorescence images acquired from the control artery, which did not reveal PNP fluorescence upon focusing on either the endothelium (top) or the smooth muscle layer (bottom) (nuclei in blue). c, Fluorescence images acquired from the denuded artery, which revealed significant PNP retention as fluorescent punctates (PNP fluorescence in red) above the smooth muscle layer. d, Fluorescence image of arterial cross-section acquired from the control artery, which showed nuclei of endothelial cells above the collagen layer (autofluorescence in green) and an absence of PNP fluorescence. e, Fluorescence image of arterial cross-section acquired from the denuded artery, which showed PNP retention as fluorescent punctates on the collagen layer (PNP fluorescence in red; collagen autofluorescence in green) and an absence of endothelial cell nuclei. All scale bars, 100 mm.
